Lake Street Maintains Buy on Achieve Life Sciences, Lowers Price Target to $11
Portfolio Pulse from Benzinga Newsdesk
Lake Street analyst Thomas Flaten maintains a Buy rating on Achieve Life Sciences (NASDAQ:ACHV) but lowers the price target from $19 to $11.
March 05, 2024 | 1:52 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Lake Street analyst Thomas Flaten maintains a Buy rating on Achieve Life Sciences but lowers the price target from $19 to $11.
While the maintenance of a Buy rating suggests continued confidence in the company's fundamentals, the reduction in the price target could indicate concerns about near-term challenges or valuation adjustments. This mixed signal might lead to short-term market uncertainty for ACHV's stock.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100